The results of a recent retrospective analysis show that long-term treat­ment with the combination of Revlimid, clarithromycin (Biaxin), and dexa­methasone – commonly abbreviated "BiRd" – is effective and safe in newly diagnosed myeloma patients.

Furthermore, the study did not find any significant association between long-term Revlimid (lenalidomide) therapy and an increased risk of developing secondary cancers.

“We did expect these results. It was our sense from following patients who have been treated with lena­lido­mide [Revlimid] long-term and have not received any genotoxic therapy that we did not see increased rates of second primary malignancies,” said …